Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares

EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2

Related Keywords

Germany ,China ,Ingelheim ,Rheinland Pfalz ,Japan ,Laura Lessenich ,Carinne Brouillon ,European Union ,Corporate Communications ,Boehringer Ingelheim ,Managing Directors ,Human Pharma ,Mainland China ,Media Contact ,Ffisayil 2 ,Spesolimab ,Ntibody ,Generalized Pustular Psoriasis ,Clinical Trials ,Rare Skin Disease ,Plaque Psoriasis ,Pevigo ,Gpp Flares ,Nterleukin 36 Receptor ,Il 36 ,Ffisayil ,Ffisayil 1 ,Ffisayil On ,